Emerging gene therapy administered through a one-time subretinal injection marks a major milestone for the inherited retinal disease community Initial data expected in Q1 2026 Nov. 13, 2025 -- Opus Genetics, (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the first participant has been dosed in the Company’s OPGx

AI-discovered candidate CHM-029 demonstrates robust, dose-dependent tumor regression in pre-clinical AML models and retains potency against all known resistance mutations First-in-human trials expected to begin in Q2 2026 13 November 2025 -- CHARM Therapeutics (“CHARM”, “The Company”), today announced the advancement of CHM-029, a next-generation pan-menin inhibitor designed to overcome resistance mutations, as a development candidate for the treatment of acute myeloid leukemia (AML). It is exp

$32 million new equity injection adds to previously announced $59 million New investors Tencent and BGF joined by all existing major shareholders Funds will advance pipeline of novel TCR-CD3 bispecifics in cancer and autoimmune disease 13 November 2025 – T-Therapeutics, a biotechnology company developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune disease, today announces the successful expansion of its Series A financing, raising a further $32 million. Followi

Strategic transaction supports the advancement of Decoy’s rapid computational design and manufacturing of innovative peptide conjugate therapeutics through its IMP3ACT™ platform Combined company has pro forma cash of $14 million following merger and closing of recent public offering Nov. 13, 2025 -- Salarius Pharmaceuticals (Nasdaq: SLRX) (“Salarius” or the “Company”) and Decoy Therapeutics (“Decoy”) announce the completion of their strategic merger with the combined company now focused on adv

New funding brings total capital raised to $135 million Molecular gates offer the convenience of a pill with potential for superior efficacy through a novel mechanism that eliminates disease-causing proteins at their source Financing will support clinical development of differentiated small molecule therapies targeting high-value inflammatory and neurological disease proteins Nov. 13, 2025 -- Gate Bioscience, a biotechnology company developing a new class of small molecule medicines aiming to

Nov. 13, 2025 -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the company has reached target enrollment of 540 participants in the randomized, placebo-controlled Phase 2 ‘START’ Study. A number of additional patients are in the final stages of screening and will be randomized if they meet all eligibility requirements. START will assess the safety and activity of zervimesi

Prescription Drug User Fee Act (PDUFA) goal date of December 31, 2025 Nov. 13, 2025 -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab

Nov. 12, 2025 -- Chiesi Group today announced it has entered into an exclusive license agreement with Aliada Therapeutics, a wholly owned subsidiary of AbbVie, to advance blood-brain barrier (BBB)-crossing platform technology in lysosomal storage disorders (LSD) to address challenging disease areas with high unmet need. “This agreement underscores our continued commitment to creating potential solutions that target the significant unmet needs in managing cognitive and neurological symptoms acr

Preclinical research to be conducted at the University of North Carolina at Chapel Hill (UNC) Annamycin will be used in conjunction with novel agents and modalities Preclinical studies indicate Annamycin targets key factors in pancreatic cancer Nov. 12, 2025 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced it has entered i

RPT1G is the first well-tolerated NAMPT inhibitor, demonstrating safety in healthy volunteers at single and multiple ascending dose levels. Target engagement data indicate that RPT1G inhibits NAMPT in humans at doses predicted to be therapeutically relevant for hematologic malignancies. FDA has cleared Remedy Plan's IND application for RPT1G in R/R AML and HR-MDS. Remedy Plan granted orphan drug designation for RPT1G in AML. Nov. 12, 2025 -- RPT1G, a revolutionary new NAMPT inhibitor develope